China Intelligence
China market coverage your competitors don't have
Sleuth helps biopharma teams get to conviction faster, turning complex strategic questions into clear, evidence-backed answers in hours instead of months.
the china blindspot
China can't be a blind spot
18,000+
Chinese assets and growing — buried in Mandarin-language sources your current tools don't reach. Missing them has implications across your business.
~50%
of ADCs, bispecifics & CAR-T worldwide
You can't assess biopharma landscapes with Western data alone
~50% of all ADCs, bispecifics, and CAR-T programs worldwide come from Chinese sponsors.
2,000+
innovative INDs
/ year
/ year
Your next competitor is already in development in China
China accepts over 2,000 innovative IND applications per year. Today's preclinical assets will be tomorrow's competitors.
~2,300
assets in late-stage now
A wave of clinical data is coming; rapid triage will be critical
~2,300 Chinese-origin assets are in late-stage development now. Tracking and positioning around the global standard of care is getting far more complex.
335+
out-licensing deals since 2021
Cross-border deal activity has become a core BD channel
335+ out-licensing deals since 2021. The buyer pool grew from 17 to 84 unique companies in four years.
built for action
China intelligence you can act on
Find Chinese assets earlier
Sleuth sources preclinical assets from the places they get disclosed: company websites, WeChat, conference abstracts, and patent filings. See assets at the point of disclosure — not months later when a legacy database catches up.
Chinese data you can trust
Chinese biopharma data is uniquely hard to validate, with conflicting sources and overstated claims. Sleuth continuously validates the data as new evidence arrives — and with hundreds of China-focused engagements delivered, our analyst team helps your team act with confidence.
Assess complete landscapes
Chinese and Western assets surface side-by-side in every analysis — no fragmented workflows or specialized research tracks for China. Your competitive scans, pipeline maps, and TA landscapes are comprehensive by default.
Coverage
Comprehensive China data coverage
Sleuth translates, structures, and integrates Chinese-language primary sources so they sit alongside your Western data automatically — an equivalent source for every standard category in Western databases, plus sources with no Western equivalent at all.
Regulatory
Chinese regulatory filings and decisions — drug approvals, policy changes, enforcement actions, and safety notices — indexed alongside FDA and EMA data.
Clinical Trials
China's clinical trial registries — full trial records with protocol details, enrollment status, and results.
Patents
Chinese patent filings and grants — targets, mechanisms, assignees, and filing dates — indexed alongside USPTO and EPO coverage.
Academic Research
Chinese repositories and regional conference abstracts, with ~8,000 conferences tracked.
Industry & Deal Intelligence
Chinese pharma trade press — R&D updates, regulatory decisions, M&A, licensing deals, financing, and market filings.
Company Data & WeChat
Direct monitoring of tens of thousands of company websites, plus WeChat announcements, analyst commentary, and KOL posts that never reach the open web.
Drug Pricing
Chinese drug pricing data, including NRDL (National Reimbursement Drug List) updates and provincial pricing information.
News & Social
Chinese-language news, press releases, and industry commentary — including sources inaccessible to most Western platforms.
Learn more about the Chinese Biopharma Landscape
Comprehensive China data coverage
See your therapeutic area with China included
Book a Demo
Learn more about Sleuth
Read the FAQ